Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484324 | 1.00 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL2484323 | 1.00 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL6848903 | 0.76 | TSHR (0.42) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL13648285 | 0.71 | TDP1 (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL12608574 | 0.70 | — | — | |
| SCHEMBL11553089 | 0.70 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL17839047 | 0.69 | TSHR (0.36) | TSHR | |
| SCHEMBL31374111 | 0.68 | TSHR (0.39) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL4352926 | 0.65 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11981298 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221194-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170260202-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9676791-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9527865-B2 | — | — | 2016-12-27 | — | — | US | disclosed |
| US-20130245256-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-09-19 | — | — | US | disclosed |
| US-8278314-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221194-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, FLT3, RET | TSHR 151/4885CHRM2 930/4885CHRM4 1118/4885 |
| US-20130245256-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | TSHR 783/4885CHRM2 3126/4885CHRM4 3226/4885 |
| US-20170260202-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | TSHR 516/4885CHRM2 3320/4885CHRM4 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.